Corbus Pharmaceuticals (CRBP) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, gaining 40.0% versus a loss of 65.7%. Over five years, CRBP leads with a -82.4% price change compared with -88.8% for PDSB. Corbus Pharmaceuticals is the larger company by market cap ($104.1 million vs $100.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBP | PDSB |
|---|---|---|
| Share price | $5.38 | $1.38 |
| Market cap | $104.06M | $100.01M |
| 1-day change | +2.09% | +35.29% |
| YTD return | -33.91% | +79.22% |
| 1-year return | -65.73% | +39.96% |
| 5-year return | -82.42% | -88.81% |
| EPS (TTM) | $-6.11 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.56 | $1.55 |
| 52-week low | $5.13 | $0.195 |
| Distance from 52-week high | -73.83% | -10.97% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +532.53% | +262.32% |
| Average volume | 765.12K | 23.24M |
| Shares outstanding | 19.34M | 72.47M |
| Employees | 36 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed CRBP by 105.7 percentage points over the past year.
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
CRBP vs PDSB FAQ
Which is bigger, Corbus Pharmaceuticals or PDS Biotechnology?
Corbus Pharmaceuticals (CRBP) is larger, with a market capitalization of $104.06M compared with $100.01M for PDS Biotechnology (PDSB).
Which stock has performed better over the past year, CRBP or PDSB?
PDSB returned +39.96% over the past 12 months, compared with -65.73% for CRBP (price return, excluding dividends). Past performance does not predict future results.
Are Corbus Pharmaceuticals and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.